The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Call Transcript February 20, 2024 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-2.08 EPS, expectations were $-1.21. Axsome Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and […]